Drug Detail:Vismodegib (Vismodegib [ vis-moe-deg-ib ])
Drug Class: Hedgehog pathway inhibitors
Vismodegib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of vismodegib during breastfeeding. Because vismodegib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 4 days and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during vismodegib therapy and for 24 months after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Vismodegib
CAS Registry Number
879085-55-9
Drug Class
Breast Feeding
Lactation
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification